Literature DB >> 9510153

The induction of acute phase proteins by lipopolysaccharide uses a novel pathway that is CD14-independent.

A Haziot1, X Y Lin, F Zhang, S M Goyert.   

Abstract

LPS (endotoxin) and proinflammatory cytokines (IL-6, IL-1, and TNF-alpha) are potent inducers of acute phase proteins (APP). Since LPS induces high levels of these cytokines after its interaction with CD14, a protein expressed on the surface of monocytes and neutrophils, it has been assumed that CD14 mediates the LPS induction of APP expression. To test this hypothesis, CD14-deficient and control mice were injected with low doses of LPS, and the expression of several APP that are normally up-regulated by LPS was measured. CD14-deficient mice showed no alteration in the induction of APP, including serum amyloid A, LPS-binding protein, fibrinogen, or ceruloplasmin; in contrast, C3H/HeJ mice, which carry a mutation in the Lps gene, do not up-regulate the expression of these proteins. These studies show that the up-regulation of APP by LPS utilizes a non-CD14 receptor and requires a functional Lps gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510153

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Neisseria gonorrhoeae porin modifies the oxidative burst of human professional phagocytes.

Authors:  D R Lorenzen; D Günther; J Pandit; T Rudel; E Brandt; T F Meyer
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  Dominant negative down-regulation of endotoxin-induced tumor necrosis factor alpha production by Lps(d)/Ran.

Authors:  Q Yuan; F Zhao; S W Chung; P Fan; B M Sultzer; Y W Kan; P M Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.

Authors:  Gaetano Zizzo; Philip L Cohen
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

4.  The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice.

Authors:  Veronica L Massey; Christine E Dolin; Lauren G Poole; Shanice V Hudson; Deanna L Siow; Guy N Brock; Michael L Merchant; Daniel W Wilkey; Gavin E Arteel
Journal:  Hepatology       Date:  2016-12-30       Impact factor: 17.425

5.  Toll-Like Receptor 4-Independent Carbon Tetrachloride-Induced Fibrosis and Lipopolysaccharide-Induced Acute Liver Injury in Mice: Role of Hepatic Stellate Cells.

Authors:  Sudhir Kumar; Jiang Wang; Shiva Kumar Shanmukhappa; Chandrashekhar R Gandhi
Journal:  Am J Pathol       Date:  2017-04-13       Impact factor: 4.307

Review 6.  Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.

Authors:  Eva M Pålsson-McDermott; Luke A J O'Neill
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

7.  Helicobacter pylori: expect the unexpected.

Authors:  Giovanni Suarez; Richard M Peek
Journal:  Mol Microbiol       Date:  2014-02-18       Impact factor: 3.501

8.  Structural Modifications of Bacterial Lipopolysaccharide that Facilitate Gram-Negative Bacteria Evasion of Host Innate Immunity.

Authors:  Motohiro Matsuura
Journal:  Front Immunol       Date:  2013-05-24       Impact factor: 7.561

9.  Phenotypic and Functional Heterogeneity of Low-Density and High-Density Human Lung Macrophages.

Authors:  Barbara Balestrieri; Francescopaolo Granata; Stefania Loffredo; Angelica Petraroli; Giulia Scalia; Paolo Morabito; Chiara Cardamone; Gilda Varricchi; Massimo Triggiani
Journal:  Biomedicines       Date:  2021-05-04

10.  Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14.

Authors:  Sachiko Akashi; Shin-ichiroh Saitoh; Yasutaka Wakabayashi; Takane Kikuchi; Noriaki Takamura; Yoshinori Nagai; Yutaka Kusumoto; Koichi Fukase; Shoichi Kusumoto; Yoshiyuki Adachi; Atsushi Kosugi; Kensuke Miyake
Journal:  J Exp Med       Date:  2003-09-29       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.